8383 bet365

Rico Carty, who won the 1970 NL batting title when he hit a major league-best .366 for the Atlanta Braves, has died. He was 85. Read this article for free: Already have an account? To continue reading, please subscribe: * Rico Carty, who won the 1970 NL batting title when he hit a major league-best .366 for the Atlanta Braves, has died. He was 85. Read unlimited articles for free today: Already have an account? Rico Carty, who won the 1970 NL batting title when he hit a major league-best .366 for the Atlanta Braves, has died. He was 85. Major League Baseball, the players’ association and the Braves paid tribute to Carty on social media on Sunday. No further details on Carty’s death were provided. “Carty was one of the first groundbreaking Latino stars in the major leagues, and he established himself as a hero to millions in his native Dominican Republic, his hometown of San Pedro de Macoris, and the city of Atlanta, where he was a beloved fan favorite,” the players’ association said in its statement. The Braves said Carty left an indelible mark on the organization. “While his on-field accomplishments will never be forgotten, his unforgettable smile and generous nature will be sorely missed,” the team said in its statement. Carty made his big league debut with the Braves in September 1963. He batted .330 with 22 homers and 88 RBIs in his first full season in 1964, finishing second to Dick Allen in voting for NL Rookie of the Year. The Braves moved from Milwaukee to Atlanta after the 1965 season, and Carty got the franchise’s first hit in its new home on April 12, 1966, against Pittsburgh. Carty had his best year in 1970, batting .366 with 25 homers and a career-best 101 RBIs. He started the All-Star Game after he was elected as a write-in candidate, joining Willie Mays and Hank Aaron in the NL outfield. Carty batted .299 with 204 homers and 890 RBIs over 15 years in the majors, also playing for Cleveland, Toronto, Oakland, Texas and the Chicago Cubs. He retired after the 1979 season. ___ AP MLB: https://apnews.com/hub/MLB AdvertisementEquity Residential stock underperforms Tuesday when compared to competitors despite daily gainsSouth Korean President Yoon Suk Yeol's brief imposition of martial law marks a new warning for the worldwide fragility of democracy, even in a country hailed as a model of political transformation. Yoon's overnight attempt to shut down political activity, censor media and lock out opposition lawmakers stunned South Korea's longtime ally, the United States, which said it had no advance warning and issued a statement of concern. South Korea's transition to elected rule since a mass uprising in 1987 had been seen as so thorough that the United States increasingly spoke of its ally as a global partner. Meanwhile, Seoul billed itself as a new, ideal hub for international media as China clamped down on Hong Kong. President Joe Biden had even chosen Yoon as the host in March of his final Summit for Democracy -- a signature initiative of the outgoing US leader, who sought to champion liberal values globally, in an unstated repudiation of Donald Trump, who returns to the White House next month. But observers, while stunned by Yoon, said there were warning signs. Danny Russel, a top US diplomat for Asia under former president Barack Obama and who earlier served in South Korea, pointed to the deadlock in parliament where the opposition repeatedly sought impeachments against Yoon's administration. Yoon's move "was a complete surprise to me (but) yes, there were very obvious structural forces at work," he said. "There is a radically polarized political scene in Korea. The opposition has been pursuing scorched-earth political obstruction tactics," he said. But he pointed to the quick, large-scale protests that erupted after Yoon's declaration as a sign of a vibrant civil society ready to defend democracy. "One certainly would hope that this would serve as a wake-up call to both the ruling conservative party and the progressive opposition that both sides have gone too far and that there needs to be some process of reconciliation, of dealing with legitimate differences and grievances." Yoon himself had earlier shown signs of authoritarianism. In a national address last year, Yoon raged against supposed communists who have "disguised themselves as democracy activists, human rights advocates or progressive activists." A prosecutor, Yoon narrowly won the 2022 election on a platform of economic reform and advocated close ties with the United States as well as historic rival Japan. But his popularity swiftly slid and the opposition won the National Assembly. Celeste Arrington, a Korea expert at George Washington University, noted that Yoon had never held elected office before and had become increasingly frustrated. "This is really an extreme move that may signal, I think, the president's lack of political experience," she said. She said that martial law showed "some cracks in democracy" but that the quick reversal "gives me hope in the health and strength and vibrancy of democracy in South Korea." Bruce Klingner, a senior research fellow at the conservative Heritage Foundation, expected Yoon's career to be over after attempting martial law, which constitutionally can only be imposed for wars or other emergencies. "Yoon's action is a damning reversal to decades of South Korean efforts to put its authoritarian past behind it," he said. The number of democracies worldwide soared starting in the late 1980s as the Soviet Union collapsed and student-led uprisings brought reforms elsewhere. But globally, democracy has been in retreat for the last 18 straight years, according to the Washington-based group Freedom House, which promotes political liberty. Democratically elected leaders have taken increasingly authoritarian steps in countries as diverse as India, Turkey and Hungary. V-Dem, another closely watched democracy index, had most recently ranked South Korea third in Asia after Taiwan and Japan. In the United States, Trump has rejected long-held norms, refusing to accept he lost to Biden four years ago -- culminating in his supporters violently rampaging through the US Capitol. Trump's rejection of democracy ultimately worked out for him: campaigning on the rage of 2020, he won last month's election. But experts said Yoon's power play -- and its reversal -- could in fact show a victory for democratic values. "Yoon is a deeply unpopular and ineffectual leader, but there was nothing I saw of people being dissatisfied with the way government runs," Alan Yu, a senior vice president at the left-leaning Center for American Progress, said after a recent trip to Seoul. Darcie Draudt-Vejares of the Carnegie Endowment for International Peace, said that with the swift response to Yoon, "this crisis may ultimately strengthen Korean democracy by reaffirming civilian control and demonstrating institutional resilience." sct/nro8383 bet365 。

Amorim warns Man United fans: 'Storm will come'TD SYNNEX to Announce Fiscal 2024 Full Year and Fourth Quarter Results on January 9, 2025

Should Seahawks’ Ryan Grubb get another season? It’s time to find out.Chinese giant takes aim at Apple with new phone

Mars rover Perseverance sends home postcard from scenic 'Pico Turquino' (photo)Winning start for Van Nistelrooy as Leicester beat West Ham

Regulation could put working families’ jobs on the line and imperil our supply chainPaves way for additional large indications markets TORONTO and HAIFA, Israel, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based regenerative therapies, has announced significant findings from an expanded preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing optic nerve damage. Conducted in collaboration with the Goldschleger Eye Institute at Sheba Medical Center, consistently ranked one of the top ten hospitals in the world 1 , the study builds on previously announced preliminary results 2 on June 28, 2024 and strengthens the suggestion of a promising treatment pathway for glaucoma, the leading cause of irreversible blindness globally 3 . The Optic Nerve Disorders treatment market is expected to grow from 5.54 (USD Billion) in 2023 to 11.5 (USD Billion) by 2032, at a compound annual growth rate (CAGR) of ~8.46% during the forecast period 4 . Researchers utilized a rodent model of optic nerve crush (ONC) to simulate the damage associated with conditions like glaucoma. After inducing injury, ExoPTEN was administrated via direct injection into the eyes. The study expanded on earlier findings which indicated that eyes treated with ExoPTEN regained nearly normal retinal activity, as evidenced by electrical tests. Expanded analyses of the study data showed clear recovery of signal transmission in treated eyes compared to untreated controls, which showed no significant response. Additionally, imaging results by optical coherence tomography (OCT) scans indicates and validates that in all of treated eyes (naïve exosome treatment or ExoPTEN treatment) a successful ONC procedure has been performed (Figure 1). The study also showed that ExoPTEN treatment significantly enhanced the survival of retinal ganglion cells - key neurons responsible for transmitting visual information to the brain. Detailed analysis of retinal flat-mounts confirmed this effect, with treated eyes exhibiting substantially higher counts of these cells compared to untreated or control-treated eyes (Figures 2A and 2B). Dr. Ifat Sher, the lead investigator from the Goldschleger Eye Institute, commented, "the results from this expanded study are extremely encouraging. ExoPTEN demonstrates potential as a treatment that restores functionality and offers neuroprotection. The study shows clear signal recovery, healthier optic nerve structures and preserved retinal ganglion cells. These results suggest that ExoPTEN could fundamentally change how we approach conditions like glaucoma and optic nerve trauma. Encouraged by these results, we are advancing to a larger study with more animals to validate and expand upon these findings.” Dr. Lior Shaltiel, CEO of NurExone, added, "these findings are an important step forward in our mission to develop groundbreaking therapies for regenerative medicine in several indications. ExoPTEN's ability to repair both the structure and function of the optic nerve highlights its transformative potential for addressing vision loss and improving tens of millions of patient lives.” About NurExone NurExone Biologic Inc. is a TSX Venture Exchange (" TSXV ”) and OTCQB listed pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, minimally-invasively, to patients who have suffered Central Nervous System injuries. The Company's first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) and by the European Medicines Agency (EMA). The NurExone platform technology is expected to offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. For additional information and a brief interview, please watch Who is NurExone? , visit www.nurexone.com or follow NurExone on LinkedIn , X (formerly Twitter) , Facebook or YouTube Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: [email protected] Oak Hill Financial Inc. 2 Bloor Street, Suite 2900 Toronto, Ontario M4W 3E2 Investor Relations - Canada Phone: +1-647-479-5803 Email: [email protected] Dr. Eva Reuter Investor Relations - Germany Phone: +49-69-1532-5857 Email: [email protected] Allele Capital Partners Investor Relations - US Phone: +1 978-857-5075 Email: [email protected] FORWARD-LOOKING STATEMENTS This press release contains certain "forward-looking statements” that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as "may”, "will”, "should”, "could”, "expect”, "plan”, "intend”, "anticipate”, "believe”, "estimate”, "predict” or "potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the results of the Company's preclinical trials and its suggestion of a promising treatment pathway for glaucoma; the growth of the Optic Nerve Disorders treatment market; the Company expanding to further studies; the Company developing groundbreaking therapies for regenerative medicine in several indications; ExoPTEN having the potential to address vision loss and improve patient lives; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including : the a bility to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the Company's ability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company's ability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine; the Optic Nerve Disorders treatment market continuing to grow as stated; the Company expanding to further studies; the Company developing groundbreaking therapies for regenerative medicine in several indications; ExoPTEN addressing vision loss and improve patient lives; and the NurExone platform technology will offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to : the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the Company's inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company's inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine; the Optic Nerve Disorders treatment market decreasing and/or plateauing ; the Company 's inability to expand into further studies; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications ; and the risks discussed under the heading "Risk Factors” on pages 44 to 51 of the Company's Annual Information Form dated August 27 , 202 4 , a copy of which is available under the Company's SEDAR+ profile at www.sedarplus.ca . These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. 1 https://www.afsmc.org/2024/02/sheba-medical-center-named-a-newsweek-worlds-best-hospital-for-the-6th-consecutive-year/ 2 https://www.globenewswire.com/news-release/2024/06/28/2906122/0/en/NurExone-s-ExoPTEN-Being-Studied-as-Glaucoma-Treatment-for-US-3-4-Billion-Market.html 3 https://www.mdpi.com/1424-8247/17/10/1261 4 https://www.marketresearchfuture.com/reports/optic-nerve-disorders-treatment-market-30051 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5e682a60-3287-44b2-b7da-08ebed8fa807NEW YORK (AP) — U.S. stock indexes fell Thursday following some potentially discouraging data on the economy . The S&P 500 slipped 0.5% for its fourth loss in the last six days. It’s a pause for the index, which has been rallying toward one of its best years of the millennium . The Dow Jones Industrial Average lost 234 points, or 0.5%, and the Nasdaq composite sank 0.7% from its record set the day before. A report early in the morning said more U.S. workers applied for unemployment benefits last week than expected. A separate update, meanwhile, showed that inflation at the wholesale level, before it reaches U.S. consumers, was hotter last month than economists expected. Neither report points to imminent disaster, but they dilute one of the hopes that’s driven the S&P 500 to 57 all-time highs so far this year : Inflation is slowing enough to convince the Federal Reserve to keep cutting interest rates, while the economy is remaining solid enough to stay out of a recession. Of the two reports, the weaker update on the job market may be the bigger deal for the market, according to Chris Larkin, managing director, trading and investing, at E-Trade from Morgan Stanley. A surge in egg prices may have been behind the worse-than-expected inflation numbers. “One week doesn’t negate what has been a relatively steady stream of solid labor market data, but the Fed is primed to be sensitive to any signs of a softening jobs picture,” he said. Traders are widely expecting the Fed will ease its main interest rate at its meeting next week. If they’re correct, it would be a third straight cut by the Fed after it began lowering rates in September from a two-decade high. It’s hoping to support a slowing job market after getting inflation nearly all the way down to its 2% target. Lower rates would give a boost to the economy and to prices for investments, but they could also provide more fuel for inflation. A cut next week would have the Fed following other central banks, which lowered rates on Thursday. The European Central Bank cut rates by a quarter of a percentage point, as many investors expected, and the Swiss National Bank cut its policy rate by a steeper half of a percentage point. Following its decision, Switzerland’s central bank pointed to uncertainty about how U.S. President-elect Donald Trump’s victory will affect economic policies, as well as about where politics in Europe is heading. Trump has talked up tariffs and other policies that could upend global trade. He rang the bell marking the start of trading at the New York Stock Exchange on Thursday to chants of “USA.” On Wall Street, Adobe fell 13.7% and was one of the heaviest weights on the market despite reporting stronger profit for the latest quarter than analysts expected. The company gave forecasts for profit and revenue in its upcoming fiscal year that fell a bit shy of analysts’. Warner Bros. Discovery soared 15.4% after unveiling a new corporate structure that separates its streaming business and film studios from its traditional television business. CEO David Zaslav said the move “enhances our flexibility with potential future strategic opportunities,” raising speculation about a spinoff or sale. Kroger rose 3.2% after saying it would get back to buying back its own stock now that its attempt to merge with Albertsons is off . Kroger’s board approved a program to repurchase up to $7.5 billion of its stock, replacing an existing $1 billion authorization. All told, the S&P 500 fell 32.94 points to 6,051.25. The Dow Jones Industrial Average dropped 234.55 to 43,914.12, and the Nasdaq composite sank 132.05 to 19,902.84. In stock markets abroad, European indexes held relatively steady following the European Central Bank’s cut to rates. Asian markets were stronger. Indexes rose 1.2% in Hong Kong and 0.8% in Shanghai as leaders met in Beijing to set economic plans and targets for the coming year. South Korea’s Kospi rose 1.6% for its third straight gain of at least 1%, as it pulls back following last week’s political turmoil where its president briefly declared martial law. In the bond market, the 10-year U.S. Treasury yield rose to 4.33% from 4.27% late Wednesday. AP Business Writers Matt Ott and Elaine Kurtenbach contributed.